{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R+II%C2%AE&page=2", "query": { "intervention": "M-M-R II®", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R+II%C2%AE&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-09T01:28:26.159Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03893448", "title": "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections", "Pneumococcal Vaccines" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "RotaTeq™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "RECOMBIVAX HB™", "type": "BIOLOGICAL" }, { "name": "VAQTA™", "type": "BIOLOGICAL" }, { "name": "MMR II™", "type": "BIOLOGICAL" }, { "name": "VARIVAX™", "type": "BIOLOGICAL" }, { "name": "HIBERIX™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "90 Days", "sex": "ALL", "summary": "42 Days to 90 Days" }, "enrollment_count": 1720, "start_date": "2019-06-19", "completion_date": "2021-05-24", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Opp", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893448" }, { "nct_id": "NCT02441686", "title": "Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Stem Cell Mobilization", "type": "PROCEDURE" }, { "name": "Autologous Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-12", "completion_date": "2025-10", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 8, "location_summary": "Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02441686" }, { "nct_id": "NCT00392990", "title": "Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Regimen A", "type": "DRUG" }, { "name": "Regimen B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2007-02-06", "completion_date": "2013-05-28", "has_results": true, "last_update_posted_date": "2019-10-15", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 8, "location_summary": "Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392990" }, { "nct_id": "NCT03537508", "title": "Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Volunteers (Meningococcal Infection)" ], "interventions": [ { "name": "MenACYW conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "MenACYW-135 conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "DTaP-IPV//Hib vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "Pentavalent rotavirus vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, mumps, rubella (MMR) vaccine", "type": "BIOLOGICAL" }, { "name": "Varicella vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis A vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "42 Days to 89 Days" }, "enrollment_count": 2627, "start_date": "2018-04-25", "completion_date": "2023-09-22", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537508" }, { "nct_id": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2008-01", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617929" }, { "nct_id": "NCT00578175", "title": "Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Varicella", "Rubella", "Mumps", "Measles" ], "interventions": [ { "name": "Priorix-Tetra™ (MMRV vaccine 208136)", "type": "BIOLOGICAL" }, { "name": "ProQuad®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "14 Months", "sex": "ALL", "summary": "12 Months to 14 Months" }, "enrollment_count": 1851, "start_date": "2007-11-20", "completion_date": "2009-03-17", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 141, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Benton", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578175" }, { "nct_id": "NCT01040832", "title": "EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "EMD 1201081", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2009-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 4, "location_summary": "Aurora, Colorado • Lexington, Kentucky • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040832" }, { "nct_id": "NCT00861744", "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rubella", "Mumps", "Measles", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "GSK Biological's investigational vaccine 209762", "type": "BIOLOGICAL" }, { "name": "M-M-R® II (Merck and Co)", "type": "BIOLOGICAL" }, { "name": "Varivax®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1259, "start_date": "2009-06-03", "completion_date": "2012-06-18", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861744" }, { "nct_id": "NCT03239873", "title": "Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Varicella" ], "interventions": [ { "name": "VARIVAX® PE34 Process", "type": "BIOLOGICAL" }, { "name": "VARIVAX® 2016 Commercial Process", "type": "BIOLOGICAL" }, { "name": "M-M-R II®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "12 Months to 23 Months" }, "enrollment_count": 600, "start_date": "2017-10-17", "completion_date": "2019-04-02", "has_results": true, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239873" }, { "nct_id": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2011-03-16", "completion_date": "2021-06-25", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-09-09T01:28:26.159Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296555" } ] }